LA
JOLLA, Calif., Aug. 31,
2023 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica")
(Nasdaq: CALC), a clinical-stage biopharmaceutical company focused
on developing novel calcium release-activated calcium (CRAC)
channel inhibition therapies for acute and chronic inflammatory and
immunologic illnesses, today announced that it will host a virtual
clinical experts event on Thursday,
September 21, 2023, from 10:30
a.m. – 12 p.m. ET/
7:30 a.m. – 9
a.m. PT.
CalciMedica management will be joined by clinical experts
Joseph Miller, M.D., clinical
associate professor of Emergency Medicine at Henry Ford Health and
Michigan State University and associate
director of Emergency Care Research at Henry Ford Health, and
Georgios Papachristou, M.D., Ph.D.,
professor of Medicine, Floyd Beman Endowed Chair in
Gastroenterology and division director for Gastroenterology,
Hepatology and Nutrition at The Ohio State
University College of Medicine in discussing the Company's
lead clinical compound, Auxora™, and its potential implications in
acute pancreatitis.
Registration for the event will be available in the "Upcoming
Events" section of CalciMedica's IR website at
https://ir.calcimedica.com/ beginning at 7:30 a.m. ET on Wednesday, September 6.
About CalciMedica
CalciMedica is a clinical-stage
biopharmaceutical company focused on developing novel CRAC channel
inhibition therapies for inflammatory and immunologic diseases.
CalciMedica's proprietary technology targets the inhibition of CRAC
channels designed to modulate the immune response and protect
against tissue cell injury, with the potential to provide
therapeutic benefits in life-threatening inflammatory and
immunologic diseases for which there are currently no approved
therapies. CalciMedica's lead product candidate Auxora™, a
proprietary, intravenous-formulated CRAC channel inhibitor, has
demonstrated positive and consistent clinical results in multiple
completed efficacy clinical trials. Auxora is in development for AP
with SIRS and AIPT. CalciMedica was founded by scientists from
Torrey Pines Therapeutics and the Harvard CBR Institute for
Biomedical Research, and is headquartered in La Jolla, CA. For more information, please
visit www.calcimedica.com.
CalciMedica Contact:
Investors and Media
Argot Partners
Sarah Sutton/Kevin Murphy
calcimedica@argotpartners.com
(212) 600-1902
View original content to download
multimedia:https://www.prnewswire.com/news-releases/calcimedica-to-host-acute-pancreatitis-clinical-experts-event-on-september-21-2023-301914447.html
SOURCE CalciMedica
